What is the role of bevacizumab in the treatment of renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

The novel combination of bevacizumab (Avastin), which is a neutralizing monoclonal antibody to VEGF, and interferon has been shown to have activity against metastatic RCC. [35] A phase 3 trial by Escudier et al found bevacizumab plus interferon alfa-2a to be effective as first-line treatment in patients with metastatic RCC. [36]  FDA approved bevacizumab in combination with interferon alfa for the treatment of patients with metastatic RCC. [37]

In September 2017, FDA has approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) to treat metastatic RCC, in combination with interferon alfa. The approval was based on supportive evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data. [38]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!